Clasp Launches With $150m To Develop Personalized T-Cell Engagers
Dual Agents Target Oncogenes And HLA Proteins
Clasp Therapeutics, which emerged from labs at Johns Hopkins University and was incubated by a pair of venture capital investors, plans to achieve a clinical trial readout with its series A cash.
